1. Introduction {#sec1-marinedrugs-13-05796}
===============

Marine invertebrates have been proven to secrete a number of secondary metabolites for self-defense, and those marine natural products usually show unexpected bioactivities. For example, sarcodictyins isolated from *Bellonella albiflora* and eleutherobins obtained from *Eleutherobia aurea* showed significant cytotoxicities \[[@B1-marinedrugs-13-05796],[@B2-marinedrugs-13-05796]\]. Aberrarone discovered from gorgonian *Pseudopterogorgia elisabethae* possessed potent antibacterial effects \[[@B3-marinedrugs-13-05796]\]. Those compounds can benefit new drug development and also inspire drug design. Soft corals of the genus *Cespitularia* produce various types of terpenoids such as cembranes, neodolabellanes, cespitularanes, and verticillanes \[[@B4-marinedrugs-13-05796],[@B5-marinedrugs-13-05796],[@B6-marinedrugs-13-05796],[@B7-marinedrugs-13-05796],[@B8-marinedrugs-13-05796]\]. These compounds are reported to demonstrate cytotoxic and immune-modulatory activities \[[@B9-marinedrugs-13-05796],[@B10-marinedrugs-13-05796],[@B11-marinedrugs-13-05796],[@B12-marinedrugs-13-05796],[@B13-marinedrugs-13-05796],[@B14-marinedrugs-13-05796]\]. In our continuous research of Taiwanese soft corals, a series of nor-verticillenes and nitrogen-containing verticillanes from *C. taeniata* were isolated and reported \[[@B10-marinedrugs-13-05796],[@B11-marinedrugs-13-05796]\]. Those findings impel us to further investigate this benthos. In this paper, we describe the isolation and structural elucidation of ten new marine natural products including two nitrogen-containing verticillanes (**1** and **2**), three nitrogen-containing sesquiterpenes (**3**--**5**), two norverticillanes (**6** and **7**), and three verticillanes (**8**--**10**) from Taiwanese soft coral *C. taeniata* ([Figure 1](#marinedrugs-13-05796-f001){ref-type="fig"}).

![Structures of metabolites **1**--**10**.](marinedrugs-13-05796-g001){#marinedrugs-13-05796-f001}

2. Results and Discussion {#sec2-marinedrugs-13-05796}
=========================

The EtOAc-MeOH (1:1) extract of *C*. *taeniata* was partitioned between H~2~O and EtOAc to give an EtOAc-soluble fraction. Extensive column chromatography and HPLC purification allowed the separation of ten new compounds (**1**--**10**).

Cespilamide A (**1**), $\left\lbrack \alpha \right\rbrack_{\text{D}}^{25}$ −118.2 (CH~2~Cl~2~), had a molecular formula of C~22~H~31~O~3~N as deduced from the NMR and HRESIMS (*m*/*z* 358.2380 \[M + Na\]^+^, calcd. 358.2382) data, indicating eight indices of hydrogen deficiency. The IR spectrum revealed the presence of hydroxy (3421 cm^−1^) and conjugated amide (1695 cm^−1^) moieties. The ^1^H and ^13^C-NMR data ([Table 1](#marinedrugs-13-05796-t001){ref-type="table"} and [Table 2](#marinedrugs-13-05796-t002){ref-type="table"}) showed the presence of an amidocarbonyl (δ~C~ 177.1), a trisubstituted olefinic unit \[δ~C~ 134.8 (s), 132.3 (d); δ~H~ 5.50, d, *J* = 8.0 Hz\], a tetrasubstituted olefinic moity (δ~C~ 166.2, 133.5), and an exomethylene group \[δ~C~ 146.2 (s), 114.2 (t); δ~H~ 4.87, 4.83, each brs\]. The DEPT NMR spectrum indicated an oxygenated quarternary carbon (δ~C~ 102.8), an oxygenated methine carbon (δ~C~ 68.5 d), eight methylene carbons (δ~C~ 17.9, 24.4, 32.3, 33.0, 42.5, 43.8, 46.6, 68.8), and three methyl groups (δ~H~ 1.47, 1.19, 1.59, each 3H and s; δ~C~ 17.2, 34.3, 35.2). The ^1^H--^1^H COSY experiment ([Figure 2](#marinedrugs-13-05796-f002){ref-type="fig"}) showed three sets of correlations, H-1′′/H-2′′, H-7/H-6/H-5 and H-3/H-2/H-1/H-14/H-13, and the latter two sets of proton sequences were further connected by the HMBC correlations ([Figure 2](#marinedrugs-13-05796-f002){ref-type="fig"}) of H-18/C-3 (δ~C~ 33.0), C-4 (δ~C~ 146.2), and C-5 (δ~C~ 43.8). Furthermore, the HMBC correlations of CH~3~-16, CH~3~-17/C-15 (δ~C~ 37.9), C-1 (δ~C~ 43.5), C-11 (δ~C~ 166.2) and H-13/C-12 (δ~C~ 133.5), C-20 (δ~C~ 177.1), C-11 indicated that compound **1** possesses a 2′,2′-dimethylcyclohexene moiety. The HMBC correlations of H-9/C-7 (δ~C~ 134.8), C-8 (δ~C~ 132.3), C-10 (δ~C~ 102.8), C-11 and CH~3~-19/C-7, C-8, C-9 (δ~C~ 46.6) were used to establish the planar structure of compound **1**, except for the C1′-C2′ moiety. Comparison of the ^1^H- and ^13^C-NMR data of **1** with those of cespitulactam D revealed that they have similar verticillene skeletons \[[@B12-marinedrugs-13-05796]\]. ^1^H--^1^H COSY correlations of H-1′ (δ~H~ 3.84, m; 4.11, m)/H-2′ (δ~H~ 3.27, m; 3.90, m) and HMBC correlations of H-2′/C-10, C-20 and H-1′/C-10, C-11 suggested that there is an ethylene moiety between the C-10 oxygen function and the nitrogen of the amide moiety. The configuration of compound **1** was determined by NOESY correlations and the Mosher's ester method. It was assumed that compound **1** has the same absolute configuration at C-1 as naturally-occurring verticillene diterpenoids, such as cespitulactams, cespitularines, and toxoids \[[@B10-marinedrugs-13-05796],[@B12-marinedrugs-13-05796],[@B13-marinedrugs-13-05796]\]. NOESY ([Figure 2](#marinedrugs-13-05796-f002){ref-type="fig"}) correlations of H-1/Me-16, Me-17 and H-7/ Me-17 indicated the β-orientation of Me-16 and Me-17. Moreover, NOESY correlations of H-6/Me-19/H-9α (δ~H~ 2.83) and H-7/H-9β (δ~H~ 2.58) suggested that H-6 is α-oriented. The configuration of the hydroxy group at C-6 was further determined by Mosher's reactions to yield products **1a** and **1b**. The results, illustrated in [Figure 3](#marinedrugs-13-05796-f003){ref-type="fig"}, suggested that C-6 has the *S* configuration. A computer-generated MM2 structure for compound **1** calculated for the lowest energy is illustrated in [Figure 3](#marinedrugs-13-05796-f003){ref-type="fig"}. The result also agreed with a *S* configuration at C-6. Due to lack of NOE interaction between H-7 and Me-19, the geometry of the 7,8-double bond in **1** was deduced to be *E.*

marinedrugs-13-05796-t001_Table 1

###### 

^1^H-NMR data for compounds **1**--**10** *^a^*.

  Position   1 *^b^*          2 *^c^*               3 *^b^*         4 *^b^*         5 *^b^*                6 *^b^*               7 *^b^*                8 *^b^*               9 *^c^*               10 *^b^*
  ---------- ---------------- --------------------- --------------- --------------- ---------------------- --------------------- ---------------------- --------------------- --------------------- ---------------------
  1          1.59, m          1.44, m               1.39, m         1.59, m         1.32, m                1.66, m               2.18, m                1.60, m               1.46, m               1.43, m
                                                    1.46, m                         1.43, m                                                                                                         
  2          1.54, m          1.25, m               1.56, m         1.66, m         1.61, m                1.50, m               1.12, m                2.24, m               2.30, m               2.27, m
                              1.62, m                                                                      1.98, m                                                                                  
  3          2.11, m          1.97, m               2.01, m         2.36, m         2.00, m                2.68, m               1.93, m                2.15, m               2.08, m               2.13, m
             2.30, m          2.13, m               2.33, m                         2.31, m                                      2.25, m                                      2.18, m               
  5          2.38, m          2.19, m               2.18, m         2.18, m         2.11, m                2.28, m               2.73, dd (3.9, 12.6)   2.40, m               2.23, m               2.20, m
                                                                                                           2.50, m                                                            2.65, m               2.60, m
  6          4.37, m          4.44, dt (5.5, 8.5)   2.42, m         2.63, m         2.36, m                5.38, dt (8.4, 2.4)   4.55, dt (3.9, 9.6)    4.36, dt (3.9, 7.8)   4.50, dt (3.0, 8.5)   4.40, dt (3.0, 8.7)
                                                    2.60, m                         2.57, m                                                                                                         
  7          5.50, d (8.0)    5.28, d (8.5)                                                                5.15, d (8.4)         5.56, d (9.3)          5.51, d (7.8)         5.45, d (8.5)         5.43, d (8.7)
  9          2.58, d (13.8)   2.89, s               5.05, s         5.14, s         5.06, s                3.07, d (15.9)        2.84, d (13.5)         2.85, d (14.1)        2.51, d (14.5)        2.53, d (14.4)
             2.83, d (13.8)                                                                                3.40, d (15.9)        3.89, d (13.5)         3.02, d (14.1)        3.02, d (14.5)        3.01, d (14.4)
  12                          2.31, m                                                                      6.20, t (3.6)                                                                            
                              2.50, m                                                                                                                                                               
  13         1.63, m          1.99, m               1.87, s         1.87, s         1.88, s                2.31, m               4.39, t (3.3)          1.47, m               1.59, m               1.63, m
             2.15, m                                                                                                                                                          1.69, m               
  14         2.15, m          1.88, m               0.80, s         0.84, s         0.73, s                2.25, m               2.14, m                1.66, m               1.08, m               1.16, m
             2.35, m                                                                                                                                    2.20, m               1.86, m               1.92, m
  15                                                4.61, s         4.61, s         4.59, s                                                                                                         
                                                    4.86, s         4.87, s         4.85, s                                                                                                         
  16         1.47, s          1.11, s                                                                      1.27, s               0.77, s                1.24, s               0.94, s               0.97, s
  17         1.19, s          1.03, s                                                                      1.20, s               1.47, s                1.44, s               1.32, s               1.31, s
  18         4.83, br s       4.81, s                                                                      4.80, s               4.92, s                4.83, s               4.92, s               4.92, s
             4.82, br s       4.86, s                                                                      4.77, s               4.96, s                4.84, s               4.92, s               4.92, s
  19         1.59, s          1.67, s                                                                      1.76, s               1.89, s                1.56, s               1.82, s               1.84, s
  20                                                                                                                                                                          4.46, s               4.56, s
  1′         3.84, m          3.51, m               3.74, t (7.5)   3.72, t (7.5)   3.84, dt (7.2, 14.4)                                                3.43, m               3.50, m               3.56, m
             4.11, m                                                                                                                                    3.63, m               3.86, m               3.77, m
  2′         3.27, m          2.81, t (6.5)         2.86, t (7.5)   2.78, t (7.5)   3.03, t (7.2)                                                       1.20, t (6.9)         1.24, t (7.0)         1.15, t (6.9)
             3.90, m                                                                                                                                                                                
  4′                          7.18, d (7.0)         7.17, d (6.6)   7.01, d (8.4)   7.02, d (1.5)                                                                                                   
  5′                          7.22, t (7.0)         7.19, t (6.6)   6.74, d (8.4)   8.05, (N [H]{.ul})                                                                                              
  6′                          7.31, t (7.0)         7.26, t (6.6)                                                                                                                                   
  7′                          7.22, t (7.0)         7.19, t (6.6)   6.74, d (8.4)   7.35, d (7.8)                                                                                                   
  8′                          7.18, d (7.0)         7.17, d (6.6)   7.01, d (8.4)   7.18, t (7.2)                                                                                                   
  9′                                                                                7.10, t (7.2)                                                                                                   
  10′                                                                               7.59, d (7.8)                                                                                                   
  OAc                                                                                                      2.01 s                                                                                   

*^a^* Chemical shifts are in ppm; *J* values (Hz) are in parentheses. *^b^* Recorded in CDCl~3~ at 300 MHz. *^c^* Recorded in CDCl~3~ at 500 MHz.

marinedrugs-13-05796-t002_Table 2

###### 

^13^C-NMR data for compounds **1**--**10** *^a^.*

  Position   1 *^b^*   2 *^c^*   3 *^b^*   4 *^b^*   5 *^b^*   6 *^b^*   7 *^b^*   8 *^b^*   9 *^c^*   10 *^b^*
  ---------- --------- --------- --------- --------- --------- --------- --------- --------- --------- ----------
  1          43.5 d    47.1 d    39.5 t    39.5 t    39.2 t    43.1 d    46.8 d    44.0 d    44.2 d    44.5 d
  2          32.3 t    27.7 t    23.2 t    23.2 t    23.1 t    30.6 t    32.9 t    17.6 t    26.2 t    25.4 t
  3          33.0 t    34.3 t    36.3 t    36.3 t    36.2 t    31.3 t    39.2 t    33.6 t    37.8 t    37.9 t
  4          146.2 s   145.7 s   148.6 s   148.8 s   148.8 s   146.4 s   144.8 s   145.9 s   145.8 s   147.2 s
  5          43.8 t    43.9 t    48.9 d    49.0 d    48.8 d    41.1 t    46.8 t    43.7 t    45.8 t    47.1 t
  6          68.5 d    65.8 d    22.3 t    22.3 t    22.1 t    72.3 d    70.2 d    68.2 d    69.2 d    69.2 d
  7          134.8 d   132.5 d   139.8 s   139.8 s   140.0 s   129.0 d   132.7 d   135.6 d   133.2 d   134.1 d
  8          132.3 s   132.9 s   137.1 s   137.3 s   137.2 s   133.3 s   133.2 s   131.4 s   132.8 s   131.1 s
  9          46.6 t    47.5 d    119.1 d   119.6 d   119.1 d   50.7 t    49.4 t    47.0 t    41.0 t    41.3 t
  10         102.8 s   170.2 s   38.7 s    37.9 s    37.5 s    202.1 s   208.1 s   110.9 s   94.2 s    93.0 s
  11         166.2 s   216.0 s   170.0 s   171.1 s   170.2 s   148.0 s   92.2 s    166.6 s   72.8 s    72.4 s
  12         133.5 s   37.8 t    123.9 s   124.2 s   124.1 s   135.4 d   214.5 s   129.5 s   78.0 s    79.1 s
  13         24.4 t    25.0 t    8.4 q     8.4 q     8.4 q     23.8 t    74.8 d    32.1 t    31.6 t    26.0 t
  14         17.9 t    25.9 t    18.6 q    18.6 q    18.3 q    22.8 t    24.3 t    24.4 t    33.9 t    34.4 t
  15         37.9 s    48.9 s    107.0 t   107.1 t   106.8 t   35.4 s    46.8 s    37.4 s    37.6 s    37.5 s
  16         35.2 q    22.8 q                                  32.8 q    25.8 q    33.7 q    25.1 q    25.0 q
  17         34.3 q    19.9 q                                  24.8 q    26.5 q    24.5 q    26.0 q    26.1 q
  18         114.2 t   113.0 t                                 113.5 t   115.5 t   114.5 t   115.6 t   114.0 t
  19         17.2 q    16.7 q                                  19.5 q    17.6 q    17.1 q    17.3 q    16.5 q
  20         177.1 s                                                               170.5 s   103.5 d   107.3 d
  1′         68.8 t    40.5 t    41.0 t    41.1 t    39.9 t                        58.8 t    65.2 t    65.4 t
  2′         42.5 t    35.2 t    35.4 t    34.3 t    24.8 t                        15.1 q    15.0 q    14.8 q
  3′                   138.7 s   139.2 s   130.8 s   113.3 s                                           
  4′                   128.7 d   128.9 d   130.0 d   121.9 d                                           
  5′                   126.5 d   126.4 d   115.4 d                                                     
  6′                   128.6 d   128.5 d   154.6 s   124.7 s                                           
  7′                                                 111.1 d                                           
  8′                                                 121.9 d                                           
  9′                                                 119.3 d                                           
  10′                                                118.6 d                                           
  11′                                                127.6 s                                           
  OAc                                                          170.1 s                                 
                                                               21.3 q                                  

*^a^* Multiplicities (s = C, d = CH, t = CH~2~, q = CH~3~) and assignments made by HMQC and HMBC techniques. *^b^* Recorded in CDCl~3~ at 75 MHz. *^c^* Recorded in CDCl~3~ at 125 MHz.

![COSY (bold bond), HMBC (arrow) and selected NOESY correlations of **1**.](marinedrugs-13-05796-g002){#marinedrugs-13-05796-f002}

![Mosher reaction products (**1a**, **1b**), Data are difference values of Δ*~S~*~-*R*~ (ppm); and computer-generated perspective model of **1**.](marinedrugs-13-05796-g003){#marinedrugs-13-05796-f003}

Cespilamide B (**2**), $\left\lbrack \alpha \right\rbrack_{\text{D}}^{25}$ −8.0 (CH~2~Cl~2~), was assigned a molecular formula of C~27~H~39~O~3~N, as deduced from the HRESIMS (*m*/*z* 448.2825 \[M + Na\]^+^, calcd. 448.2827), indicating nine indices of hydrogen deficiency. The presence of hydroxy, amide, and benzyl functionalities was indicated by IR absorptions at 3371, 1701, and 1647 cm^−1^. The ^1^H and ^13^C-NMR spectra revealed the presence of a ketocarbonyl (δ~C~ 216.0), an amide carbonyl (δ~C~ 170.2), a trisubstituted olefin \[δ~C~ 132.9 (s), 132.5 (d); δ~H~ 5.28, d, *J* = 8.5 Hz\], a 1,1-disubstituted olefin (δ~C~ 145.7) with an exomethylene group (δ~C~ 113.0; δ~H~ 4.86, 4.81, each s), an oxygenated methine carbon (δ~C~ 65.8), and a phenyl group \[δ~C~ 138.7 (s), 128.7 (d, 2C), 126.5 (d, 2C), 128.6 (d); δ~H~ 7.18, d, *J* = 7.0 Hz (2H), δ~H~ 7.22 t, *J* = 7.0 Hz, δ~H~ 7.31 t, *J* = 7.0 Hz (2H)\]. Thus, eight degrees of unsaturation were counted, leaving one further ring to be elucidated. The ^1^H--^1^H COSY ([Figure 4](#marinedrugs-13-05796-f004){ref-type="fig"}) correlations of H-7/H-6/H-5, H-3/H-2/H-1/H-14/H-13/H-12, NH (δ~H~ 5.71, brs)/H-1′/H-2′ and H-4′/H-5′/H-6′/H-7′/H-8′ revealed the sequences of three fragments including H-5 to H-7, H-3 to H-12 and a benzylethyl amine side chain. The HMBC correlations ([Figure 4](#marinedrugs-13-05796-f004){ref-type="fig"}) of H-9/C-10, C-8, H-12/C-11, Me-16/C-11, Me-17/C-11 and H-1′/C-10 permitted assignment of the two carbonyls at C-10 and C-11. Also, it established the connectivity between C-10 and C-1′. The absence of HMBC correlations between H-9/C-11, and H-12/C-10 indicated that compound **2** represents an unusual C-20 norditerpenoid \[[@B13-marinedrugs-13-05796]\] with bond cleavage between C-10 and C-11. The relative configuration of compound **2** was determined by NOESY experiments ([Figure 5](#marinedrugs-13-05796-f005){ref-type="fig"}) and computer-generated perspective models using the MM2 force field calculation. A NOESY correlation between Me-19 and H-6, and the lack of a correlation between Me-19 and H-7 suggested that the 7,8-double bond has an *E* geometry, similar to compound **1**.

![COSY (bold bond) and HMBC (arrow) correlations of **2**.](marinedrugs-13-05796-g004){#marinedrugs-13-05796-f004}

![Selected NOESY correlations and computer-generated perspective model of **2**.](marinedrugs-13-05796-g005){#marinedrugs-13-05796-f005}

The HRESIMS determined the molecular formula of compound **3** as C~23~H~27~ON (*m*/*z* 356.1992 \[M + Na\]^+^, calcd. 356.1990) and indicated eleven degrees of unsaturation. The IR absorption of 1676 cm^−1^ suggested the presence of a conjugated amide group. The ^1^H, ^13^C ([Table 1](#marinedrugs-13-05796-t001){ref-type="table"} and [Table 2](#marinedrugs-13-05796-t002){ref-type="table"}) and DEPT NMR spectroscopic data revealed the presence of an amide carbonyl (δ~C~ 170.0), a trisubstituted olefin \[δ~C~ 137.1 (s), 119.1 (d); δ~H~ 5.05, s\], an exomethylene group \[δ~C~ 148 (s), 107.0 (t); δ~H~ 4.86, 4.61, each s\], a tetrasubstituted olefin (δ~C~ 123.9, 139.8), a phenyl group \[δ~C~ 139.2 (s), 128.9 (d, 2C), 126.4 (d, 2C), 128.5 (d); δ~H~ 7.17, d, *J* = 6.6 Hz (2H), δ~H~ 7.19, t, *J* = 6.6 Hz (2H), δ~H~ 7.26, t, *J* = 6.6 Hz\], an aliphatic CH group (δ~H~ 2.18, m; δ~C~ 48.9), and four aliphatic CH~2~ group (δ~C~ 39.5, 23.2, 36.2, 22.3). The above findings accounted for five of the eight degrees of unsaturation, indicating that compound **3** is a tricyclic sesquiterpene with a phenyl group. ^1^H--^1^H COSY spectrum of **3** showed four sets of correlations, H-1/H-2/H-3, H-5/H-6, H-1′/H-2′, and H-4′/ H-5′/ H-6′/ H-7′/ H-8′. The HMBC correlations ([Figure 6](#marinedrugs-13-05796-f006){ref-type="fig"}) of H~2~-15/C-2, C-4, C-5 confirmed an exocyclic double bond between C-3 and C-5. The HMBC correlations of CH~3~-13/C-12, C-11, C-7; Me-14/C-10, C-1, C-9, C-5, and H-9/C-10, C-8, C-7 not only suggested the occurrence of double bonds between C-7/C-12 and C-8/C-9 but also assign the methyl group at C-10 and C-12. The presence of an α,β-unsaturated δ-lactam was inferred from the IR and HMBC spectra. Moreover, the HMBC correlations of H-1′/C-11, C-8 and H-2′/C-3′, C-4′, C-8′ indicated an amide carbonyl at C-11 and a phenylethyl side chain attached to a nitrogen atom. The relative configuration of **3** was determined on the basis of NOESY experiment and comparison with the optical rotation and NMR data of recent published compounds, taenialactams A and B, which were isolated from *C. taeniata* \[[@B14-marinedrugs-13-05796]\]. Assuming that H-5 possesses an α-orientation similar to that of taenialactams, the lack of NOESY correlation between H-5 and Me-14, suggested that Me-14 is β-oriented ([Figure 7](#marinedrugs-13-05796-f007){ref-type="fig"}).

![COSY (bold bond), HMBC (arrow) correlations of **3**.](marinedrugs-13-05796-g006){#marinedrugs-13-05796-f006}

![Selected NOESY correlation of **3**.](marinedrugs-13-05796-g007){#marinedrugs-13-05796-f007}

The molecular formula of **4** was determined to be C~23~H~27~O~2~N (Δ = 11) by HRESIMS data (*m*/*z* 372.1937 \[M + Na\]^+^, calcd. 372.1939). The IR spectrum revealed the presence of hydroxy (3421 cm^−1^) and α,β-unsaturated γ-lactam (1695 cm^−1^) moieties. The ^1^H and ^13^C NMR spectra ([Table 1](#marinedrugs-13-05796-t001){ref-type="table"} and [Table 2](#marinedrugs-13-05796-t002){ref-type="table"}) of compound **4** were similar to those of **3**, suggesting structural similarity with the exception that compound **4** contains a *para*-hydroxyphenylethyl side chain \[δ~H~ 7.01, d, *J* = 8.4 Hz (2H), 6.74, d, *J* = 8.4 Hz (2H); δ~C~ 154.6 (s), 130.8 (s), 130.0 (d), 115.4 (d), 41.0 (t), 34.3 (t)\] on the nitrogen atom, rather than a phenylethyl group as found in compound **3**. Interpretation of ^1^H--^1^H COSY and HMBC spectra of compound **4** also indicated the presence of a hydroxy group at C-6′. The relative configuration of compound **4** was determined by comparison with the NMR and the optical rotation of compound **3**.

The molecular formula of compound **5** was shown to be C~25~H~28~ON~2~ (Δ = 13), as deduced from HRESIMS at *m*/*z* 395.2099 (\[M + Na\]^+^, calcd. 395.2099). Spectroscopic data of compound **5** were found to be similar to those of **3** and **4** except for the evidence of an ethylindole moiety. The LRMS of compound **5** exhibited a peak at *m*/*z* 229 \[M + H − C~10~H~10~N\]^+^, also consistent with the presence of an ethylindole group. In the ^1^H and ^13^C NMR spectra ([Table 1](#marinedrugs-13-05796-t001){ref-type="table"} and [Table 2](#marinedrugs-13-05796-t002){ref-type="table"}), signals for a 3-ethylindole group \[δ~H~ 3.84, dt, *J* = 14.4, 7.2 Hz, 3.03, t, *J* = 7.2 Hz, 7.02, d, *J* = 1.5 Hz, 7.35, d, *J* = 7.8 Hz, 7.18, t, *J* = 7.2 Hz, 7.10, t, *J* = 7.2 Hz, 7.59, t, *J* = 7.8 Hz, 8.05, s (NH); δ~C~ 39.9 (t), 24.8 (t), 113.3 (s), 121.9 (d), 124.7 (s), 111.1 (d), 121.9 (d), 119.3 (d), 118.6 (d), and 127.6 (s)\] were also observed. The 3-ethylindole group on the tertiary nitrogen in **5** was revealed by detailed analysis of 2D NMR spectra ([Figure 8](#marinedrugs-13-05796-f008){ref-type="fig"}). The HMBC correlations of H-1′/C-11 (δ~C~ 170.2), C-8 (δ~C~ 137.2) as well as correlations of H-2′/C-3′, C-4′ and C-11′ indicated that the phenylethyl side chain at the nitrogen in compound **3** was replaced by the 3-ethylindole group in compound **5**. Assignment of the ^1^H and ^13^C-NMR spectroscopic data of **5** were accomplished by application of ^1^H--^1^H COSY, HMQC, and HMBC correlations. The relative configuration of compound **5** was assigned the same as those of compounds **3** and **4**.

![COSY (bold bond) and HMBC (arrow) correlations of **5**.](marinedrugs-13-05796-g008){#marinedrugs-13-05796-f008}

Cespitaenin A (**6**) was isolated as a colorless, amorphous solid. The molecular formula, C~21~H~30~O~3~, was established by the HRESIMS at *m*/*z* 353.2096 \[M + Na\]^+^ (calcd. 353.2093). The IR bands at 1720 and 1706 cm^−1^ were attributed to an ester and a carbonyl group, which were confirmed by the presence of the acetate (δ~C~ 170.1) and ketocarbonyl (δ~C~ 202.1). The ^13^C-NMR ([Table 2](#marinedrugs-13-05796-t002){ref-type="table"}) and DEPT spectra of compound **6** revealed 21 carbons including three methyl carbons (δ~C~ 19.5, 24.8, and 32.8), six aliphatic methylene carbons (δ~C~ 30.6, 31.3, 41.1, 50.7, 23.8 and 22.8), a methine carbon (δ~C~ 43.1), an oxygenated methine carbon (δ~C~ 72.3), an aliphatic quaternary carbon (δ~C~ 35.4), two olefinic methine carbons (δ~C~ 129.0 and 135.4), an olefinic methylene carbon (δ~C~ 113.5), three olefinic quaternary carbons (δ~C~ 146.4, 133.3, and 148.0), and two additional carbonyl signals. The ^1^H--^1^H COSY spectrum showed the connectivities of H-7/H-6/H-5 and H-3/H-2/H-1/H-14/H-13/H-12. Resonances at δ~C~ 133.3 (C-8) and 129.0 (C-7) were correlated in the HMBC spectrum with proton signals at δ~H~ 5.15 (d, *J* = 8.4 Hz, H-7), and with the vinylic methyl protons at δ~H~ 1.76 (Me-19), and suggested that compound **6** contains an *E*-trisubstituted double bond bearing a methyl group \[[@B14-marinedrugs-13-05796]\]. In addition, a trisubstituted double bond \[δ~C~ 148.0 (s), 135.4 (d), δ~H~ 6.30, t, *J* = 8.4 Hz\] and a 1,1-disubstituted olefin (δ~C~ 144.7) with an exomethylene group (δ~C~ 115.5; δ~H~ 4.87, 4.95, each s) were also implied by interpretation of the HMBC data of compound **6**. Moreover, HMBC correlations of δ~H~ 5.38 (dt, *J* = 8.4, 2.4 Hz, H-6) with δ~C~ 170.1 indicated that C-6 (δ~C~ 72.3) is attached to an acetoxy group (δ~C~ 21.3). HMBC correlations of H-12/C-11, C-10, C-15, H-9/C-10, C-11, Me-16/C-11, C-15, C-1 and Me-17/C-11, C-15, C-1, H-18/C-3, C-5 established the final structure of **6**. The relative configuration of **6** was determined by NOESY analysis and comparison of the coupling constants of **6** with the data reported \[[@B14-marinedrugs-13-05796],[@B15-marinedrugs-13-05796],[@B16-marinedrugs-13-05796],[@B17-marinedrugs-13-05796]\]. Assuming that H-1 is at the β position, the correlations between H-1/Me-16/Me-17 indicated the β-disposition of Me-16 and Me-17. The spin pattern and coupling constants of H-6, and NOESY correlations of H-6/Me-19/H-9α and H-7/H-9β agreed with a β-orientation of the acetoxy group at C-6.

Cespitaenin B (**7**), $\left\lbrack \alpha \right\rbrack_{\text{D}}^{25}$ −109 (CH~2~Cl~2~), was isolated as a colorless, amorphous solid. Its molecular formula was determined to be C~19~H~28~O~5~ (Δ= 6) from HRESIMS at *m*/*z* 359.1837 \[M + Na\]^+^. Its IR bands showed the presence of a hydroxy (3397 cm^−1^) and conjugated carbonyl (1697 cm^−1^) groups. The ^1^H and ^13^C-NMR spectroscopic ([Table 1](#marinedrugs-13-05796-t001){ref-type="table"} and [Table 2](#marinedrugs-13-05796-t002){ref-type="table"}) and DEPT data indicated the presence of two ketocarbonyls (δ~C~ 214.5 and 208.1), a trisubstituted olefin \[δ~C~ 133.4 (s), 132.7 (d); δ~H~ 5.56, d, *J* = 9.3 Hz\], and an exocyclic double bond \[δ~C~ 144.8 (s), 115.5 (t); δ~H~ 4.92, 4.96, each s). In the aliphatic region, a quaternary carbon (δ~C~ 46.8), two oxygenated methine carbons (δ~C~ 70.2 and 74.8), an oxygenated tertiary carbon (δ~C~ 92.2), five methylene carbons (δ~C~ 32.9, 39.2, 46.8, 49.4, and 24.3), and three methyl groups (δ~C~ 25.8, 26.5, and 17.6; δ~H~ 0.77, 1.47, and 1.89, each s) were observed. HMQC correlations of δ~H~ 4.55 (dt, *J* = 9.6, 3.9 Hz, H-6) with δ~C~ 70.2 (d, C-6) and δ~H~ 4.39 (t, *J* = 3.3 Hz, H-13) with δ~C~ 74.8 (d, C-13) suggested that C-6 and C-13 are hydroxylated. The ^1^H--^1^H COSY spectrum indicated the connectivities of H-7/H-6/H-5 and H-3/H-2/H-1/H-14/H-13 to be similar with those of compound **6** ([Figure 9](#marinedrugs-13-05796-f009){ref-type="fig"}). The two ketocarbonyls assigned at C-10 and C-12, and the hydroxyl group assigned at C-11 were deduced from the interpretation of HMBC correlations of H-9/C-10, C-11; H-13/C-12, C-11; Me-16, Me-17/C-1, C-11, C-15; O[H]{.ul}-11 (δ~H~ 3.13, br s)/C-11, C-10, C-12. The remaining HMBC correlations of Me-16/C-15, C-1, Me-17/C-15, C-1 also indicated that compound **7** has the same 6/12 bicyclic system as compound **6**. The NOESY spectrum showed correlations of H-1/Me-16, Me-17, O[H]{.ul}-11/Me-16 indicating that the hydroxy on C-11 is β*-*oriented, while H-6 is α*-*oriented due to the correlations of H-6/Me-19/H-9α (δ~H~ 3.89) and H-7/Me-17/H-9β (δ~H~ 2.84). The lack of correlations of H-13/H-1, Me-16, Me-17 was consistent with an α-orientation of H-13.

![COSY (bold bond) and HMBC (arrow) correlations of **7**.](marinedrugs-13-05796-g009){#marinedrugs-13-05796-f009}

The molecular formula of cespitaenin C (**8**) was determined to be C~22~H~32~O~4~, as derived from a *quasi*-molecular ion at *m*/*z* 361.2378 (\[M + Na\]^+^, calcd. 361.2379), and seven indices of hydrogen deficiency. The IR spectrum displayed absorption bands suggestive of hydroxyl (3385 cm^−1^) and ester carbonyl (1738 cm^−1^) moieties. The ^1^H and ^13^C-NMR spectra ([Table 1](#marinedrugs-13-05796-t001){ref-type="table"} and [Table 2](#marinedrugs-13-05796-t002){ref-type="table"}) exhibited an exomethylene double bond \[δ~C~ 145.9 (s), 114.5 (t); δ~H~ 4.83, 4.84, each s\], a trisubstituted double bond \[δ~C~ 131.4 (s), 135.6 (d); δ~H~ 5.51, d, *J* = 7.8 Hz, H-7), a tetrasubstituted double bond (δ~C~ 166.6, C-11; 129.5, C-12), and an ester carbonyl (δ~C~ 170.5), accounting for four degrees of unsaturation. These findings implied that **8** is a tricyclic compound. The ^1^H--^1^H COSY correlations of H-7/H-6/H-5, H-3/H-2/H-1/H-14/H-13, and H-1′/H-2′, along with the HMBC correlations of H~2~-9/C-10, C-11, H-13/C-12, C-11, C-20; Me-16/C-11, C-12; Me-17/C-11, C-12 clearly indicated that compound **8** contains a common verticillene skeleton. HMBC correlations of H-1′/C-10 suggested the ethoxy group at C-10 and thus a carbonyl at C-20 (δ~C~ 170.5). The relative configuration of compound **8** was deduced from the NOESY analysis and comparison with chemical shifts and coupling constants of cespihypotin V \[[@B18-marinedrugs-13-05796]\]. The NOESY correlations of H-1′/Me-16, H-1/Me-17/Me-17 and H-6/Me-19 indicated that Me-16, Me-17, H-1, and the OEt were β-oriented, while H-6 is α-oriented.

The HRESIMS data of cespitaenin D (**9**) established the molecular formula of C~22~H~34~O~5~ (*m*/*z* 401.2306, \[M + Na\]^+^), and indicated six indices of hydrogen deficiency. The IR spectrum displayed an absorption band indicative of hydroxy (3444 cm^−1^) group. The ^1^H and ^13^C-NMR spectroscopic data ([Table 1](#marinedrugs-13-05796-t001){ref-type="table"} and [Table 2](#marinedrugs-13-05796-t002){ref-type="table"}) showed an exomethylene double bond (δ~C~ 145.8 (s), 115.6 (t); δ~H~ 4.92, s, 2H), a trisubstituted double bond \[δ~C~ 133.2 (d), 132.8 (s); δ~H~ 5.45, d, *J* = 8.5 Hz, H-7), and a tetrasubstituted double bond, revealing two degrees of unsaturation. This implied that compound **9** possesses a tetracyclic ring system. The similar ^1^H, ^13^C-NMR, COSY, and HMBC data suggested that **9** should have the same verticillene skeleton as **8**. However, HMBC correlations of H-1′/C-20; H-13/C-12, C-11, C-20; H-20/C-12, C-11; Me-16, Me-17/C-11 indicated an ethoxy group at C-20 (δ~C~ 103.5) and an epoxy ring at C-11 (δ~C~ 72.8) and C-12 (δ~C~ 78.0). The epoxy ring at C-11 and C-12 was tentatively assigned the α-configuration due to the steric hindrance of the two β-faced methyl groups (Me-16 and Me-17). NOESY correlations ([Figure 10](#marinedrugs-13-05796-f010){ref-type="fig"}) among H-1/Me-16, Me-17, H-6/Me-19/H-9α (δ~H~ 3.01) and H-7/H-9β (δ~H~ 2.53), and lack of NOESY correlation between H-20 and Me-17 indicated the β*-*orientation of the ethoxy group at C-20 and the α-disposition of H-6.

![Selected NOESY correlation of **9**.](marinedrugs-13-05796-g010){#marinedrugs-13-05796-f010}

Cespitaenin E (**10**) was found to have the same molecular formula, C22H34O5, as **9**. It displayed as a sodium adduct ion at *m*/*z* 401.2305 (\[M + Na\]+) in the HRESIMS. There were very few differences between the 1H-NMR spectroscopic data ([Table 1](#marinedrugs-13-05796-t001){ref-type="table"}) of **9** and **10**. Comparison of their 13C-NMR spectra ([Table 2](#marinedrugs-13-05796-t002){ref-type="table"}) revealed that the differences occurred in the chemical shifts of C-13 (δC 26.0, **10**; 31.6, **9**) and C-20 (δC 107.3, **10**; 103.5, **9**). Furthermore, the COSY and HMBC correlations were closely comparable (Supporting Information). The NOESY correlations of H-20/Me-17 in **10** confirmed the β*-*orientation of H-20. The only difference between **9** and **10** is the configuration of the ethoxy group at C-20. The optical rotations of **10** \[$\left\lbrack \alpha \right\rbrack_{\text{D}}^{25}$ 0.1 (CH2Cl2)\] and **9** \[$\left\lbrack \alpha \right\rbrack_{\text{D}}^{25}$ −20.6 (CH~2~Cl~2~)\] supported the conclusion to be made that compound **10** is the 20-epimer of cespitaenin D.

A postulated biosynthetic pathway for compounds **1** and **2** is illustrated in [Scheme 1](#marinedrugs-13-05796-f011){ref-type="scheme"}. Compound **1** is probably produced from cespitularin C \[[@B19-marinedrugs-13-05796]\] via intermediates **a**--**d**, involving steps of oxidation, serine transformation, lactamization, decarboxylation, hydroxylation, and dehydration. Compound **2** may be generated from the nor-verticillene **a** through intermediates **e** and **f**. These reactions deal with decarboxylation, cleavage of the double bond between C-10 and C-11 \[[@B19-marinedrugs-13-05796]\], and phenylalanine transformation leading to an amide formation.

Four human cancer cell lines were chosen to test the *in vitro* cytotoxicity of compounds **1**--**10** ([Table 3](#marinedrugs-13-05796-t003){ref-type="table"}). Compound **5** exhibited cytotoxicity against human breast adenocarcinoma (MCF-7), medulloblastoma (Daoy), and cervical epitheloid carcinoma (Hela) cancer cells with IC~50~ of 17.5, 22.3, and 24.7 μM, respectively. Compound **6** showed significant cytotoxicity against human breast adenocarcinoma (MCF-7) cancer cells with the IC~50~ at 21.2 μM.

![A postulated biosynthetic pathway for compounds **1** and **2**.](marinedrugs-13-05796-g011){#marinedrugs-13-05796-f011}

marinedrugs-13-05796-t003_Table 3

###### 

Cytotoxicity of compounds **1**--**10** against human cancer cells (IC~50~, μM) *^a^.*

  Compound      Hela   Daoy   WiDr   MCF-7
  ------------- ------ ------ ------ -------
  **3**         30.9   34.8   49.5   30.6
  **5**         24.7   22.3   34.1   17.5
  **6**         28.5   31.5   36.4   21.2
  mitomycin C   0.32   0.32   0.32   0.32

*^a^* Hela: human cervical epitheloid carcinoma; Daoy: human medulloblastoma; WiDr: Human colon adenocarcinoma; MCF-7: human breast adenocarcinoma; *^b^* Compounds **1**, **2**, **4**, **7**--**10** were inactive (\>40 μM) in this assay system.

3. Experimental Section {#sec3-marinedrugs-13-05796}
=======================

3.1. General Experimental Procedures {#sec3dot1-marinedrugs-13-05796}
------------------------------------

Optical rotations were obtained on a JASCO DIP-1000 polarimeter. IR spectra were recorded using a Horiba FT-720 spectrophotometer. The ^1^H and ^13^C-NMR spectra as well as 2D NMR spectra (^1^H--^1^H COSY, HSQC, HMBC, and NOESY) were recorded in CDCl~3~ (or CD~3~OD) using Bruker DRX NMR spectrometers operating at 300 or 500 MHz for ^1^H and 75 or 125 MHz for ^13^C using the CDCl~3~ solvent peak as internal standard (δ~H~ 7.26 for ^1^H and δ~C~ 77.0 for ^13^C). Low-resolution ESIMS and HRESIMS were run on a JEOL JMS-HX 110 mass spectrometer. Silica gel 60 (Merck, Darmstadt, Germany) was used for column chromatography (CC). Precoated silica gel plate (Kieselgel 60 F-254, 1 mm, Merck, Darmstadt, Germany) was used for preparative TLC. Sephadex LH-20 (Amersham Pharmacia Biotech AB, Uppsala, Sweden) was used for separation. LiChrospher Si 60 (5 μm, 250-10, Merck, Darmstadt, Germany) and LiChrospher 100 RP-18e (5 μm, 250-10, Merck, Darmstadt, Germany) were used for NP-HPLC and RP-HPLC (Hitachi, Tokyo, Japan), respectively.

3.2. Animal Material {#sec3dot2-marinedrugs-13-05796}
--------------------

*Cespitularia taeniata* was collected in Green Island, Taiwan, in March 2004. This soft coral was identified by one of the authors (Y.-C.S.). A voucher specimen (GSC-1) has been deposited in the School of Pharmacy, National Taiwan University, Taipei, Taiwan.

3.3. Extraction and Isolation {#sec3dot3-marinedrugs-13-05796}
-----------------------------

The whole animals of *C. taeniata* (dried, 1.1 kg) were extracted with EtOAc and CH~2~Cl~2~ (1:1, each 1 L × 3) at room temperature and concentrated under reduced pressure to yield a crude extract. The crude extract was partitioned between H~2~O and EtOAc to yield an EtOAc-soluble fraction (100 g), which was chromatographed on a Si gel column (1 kg) and initially eluted with *n*-hexane (100%, 1 L), *n*-hexane/EtOAc (15:1 to 0:1, each 1 L), and finally MeOH (100%, 1 L) to give 12 fractions. Fractions six (3.1 g) and eight (1.7 g) were further separated on a Sephadex LH-20 column using CH~2~Cl~2~-MeOH (4:1) to furnish nine and five fractions (6-1\~6-9, 8-1\~8-5), respectively. Separation of fraction 6-5 (390 mg) was performed by a Si gel column (1.2 g) using a solvent mixture of *n*-hexane-CH~2~Cl~2~-MeOH (100:100:1\~5:5:1) to yield six fractions (6-2-1\~6-2-6). Fraction 6-5-3 (34 mg) was further purified with a NP-HPLC column (*n*-hexane-CH~2~Cl~2~-MeOH, 15:15:1) to give cespitaenin A (**6**, 2 mg). Fraction 6-5-4 (121 mg) and fraction 6-5-5 (68 mg) were separated with a NP-HPLC column (CH~2~Cl~2~-MeOH, 80:1) and then a RP-HPLC column was used (MeOH-H~2~O-CH~3~CN, 70:25:5) to yield cespitaenin C (**8**, 6 mg), cespitaenin D (**9**, 6 mg), cespilamide C (**3**, 5 mg) and cespitaenin E (**10**, 2.5 mg). Fraction 6-6 (310 mg) was purified with a NP-HPLC column (CH~2~Cl~2~-MeOH, 80:1) and with preparative TLC (*n*-hexane-BuOH, 12:1) to give cespilamide D (**4**, 9 mg). Fraction 6-8 (16 mg) was further purified with a RP-HPLC column (MeOH-H~2~O-CH~3~CN, 70:25:5) to yield cespilamide E (**5**, 5 mg). Fraction 8-4 (779 mg) and 8-5 (68 mg) were further separated with a NP-HPLC column (*n*-hexane-CH~2~Cl~2~-MeOH, 20:20:1) and with a RP-HPLC column (MeOH-H~2~O-CH~3~CN, 65:30:5) to yield cespilamide A (**1**, 1.5 mg), cespitaenin B (**7**, 3 mg) and cespilamide B (**2**, 3 mg).

3.4. Spectral Data {#sec3dot4-marinedrugs-13-05796}
------------------

Cespilamide A (**1**): colorless, amorphous solid; $\left\lbrack \alpha \right\rbrack_{\text{D}}^{25}$ −118 (*c* 0.2, CH~2~Cl~2~); IR (neat) ν~max~ 3421, 2936, 1695 cm^−1^; ^1^H-NMR (CDCl~3~, 300 MHz) and ^13^C-NMR (CDCl~3~, 75 MHz) data, see [Table 1](#marinedrugs-13-05796-t001){ref-type="table"} and [Table 2](#marinedrugs-13-05796-t002){ref-type="table"}, respectively; HRESIMS *m*/*z* 358.2380 (\[M + Na\]^+^, calcd for C~22~H~31~O~3~NNa^+^, 358.2382).

Cespilamide B (**2**): colorless, amorphous solid; $\left\lbrack \alpha \right\rbrack_{\text{D}}^{25}$ −8.2 (*c* 0.2, CH~2~Cl~2~); IR (neat) ν~max~ 3371, 2929, 2360, 1701, 1647 cm^−1^; ^1^H-NMR (CDCl~3~, 500 MHz) and ^13^C-NMR (CDCl~3~, 125 MHz) data, see [Table 1](#marinedrugs-13-05796-t001){ref-type="table"} and [Table 2](#marinedrugs-13-05796-t002){ref-type="table"}, respectively; HRESIMS *m*/*z* 448.2825 (\[M + Na\]^+^, calcd for C~27~H~39~O~3~NNa^+^, 448.2827).

Cespilamide C (**3**): colorless, amorphous solid; $\left\lbrack \alpha \right\rbrack_{\text{D}}^{25}$ 15.5 (*c* 0.2, CH~2~Cl~2~); IR (neat) ν~max~ 2926, 1676 cm^−1^; ^1^H-NMR (CDCl~3~, 300 MHz) and ^13^C-NMR (CDCl~3~, 75 MHz) data, see [Table 1](#marinedrugs-13-05796-t001){ref-type="table"} and [Table 2](#marinedrugs-13-05796-t002){ref-type="table"}, respectively; HRESIMS *m*/*z* 356.1992 (\[M + Na\]^+^, calcd for C~23~H~27~ONNa^+^, 356.1990).

Cespilamide D (**4**): colorless, amorphous solid; $\left\lbrack \alpha \right\rbrack_{\text{D}}^{25}$ 18.2 (*c* 0.2, CH~2~Cl~2~); IR (neat) ν~max~ 3312, 2927, 1649 cm^−1^; ^1^H-NMR (CDCl~3~, 300 MHz) and ^13^C-NMR (CDCl~3~, 75 MHz) data, see [Table 1](#marinedrugs-13-05796-t001){ref-type="table"} and [Table 2](#marinedrugs-13-05796-t002){ref-type="table"}, respectively; HRESIMS *m*/*z* 372.1937 (\[M + Na\]^+^, calcd for C~21~H~30~O~3~Na^+^, 372.1939).

Cespilamide E (**5**): colorless, amorphous solid; $\left\lbrack \alpha \right\rbrack_{\text{D}}^{25}$ 23.6 (*c* 0.2, CH~2~Cl~2~); IR (neat) ν~max~ 2929, 1659, 1340 cm^−1^; ^1^H-NMR (CDCl~3~, 300 MHz) and ^13^C-NMR (CDCl~3~, 75 MHz) data, see [Table 1](#marinedrugs-13-05796-t001){ref-type="table"} and [Table 2](#marinedrugs-13-05796-t002){ref-type="table"}, respectively; HRESIMS *m*/*z* 395.2099 (\[M + Na\]^+^, calcd for C~25~H~28~ON~2~Na^+^, 395.2099).

Cespitaenin A (**6**): colorless, amorphous solid; $\left\lbrack \alpha \right\rbrack_{\text{D}}^{25}$ 9.7 (*c* 0.2, CH~2~Cl~2~); IR (neat) ν~max~ 1720, 1706 cm^−1^; ^1^H-NMR (CDCl~3~, 300 MHz) and ^13^C-NMR (CDCl~3~, 75 MHz) data, see [Table 1](#marinedrugs-13-05796-t001){ref-type="table"} and [Table 2](#marinedrugs-13-05796-t002){ref-type="table"}, respectively; HRESIMS *m*/*z* 353.2096 (\[M + Na\]^+^, calcd for C~21~H~30~O~3~Na^+^, 353.2093).

Cespitaenin B (**7**): colorless, amorphous solid; $\left\lbrack \alpha \right\rbrack_{\text{D}}^{25}$ −109 (*c* 0.2, CH~2~Cl~2~); IR (neat) ν~max~ 3397, 2359, 2339, 1697, 1276 cm^−1^; ^1^H-NMR (CDCl~3~, 300 MHz) and ^13^C-NMR (CDCl~3~, 75 MHz) data, see [Table 1](#marinedrugs-13-05796-t001){ref-type="table"} and [Table 2](#marinedrugs-13-05796-t002){ref-type="table"}, respectively; HRESIMS *m*/*z* 359.1837 (\[M + Na\]^+^, calcd for C~19~H~28~O~5~ Na^+^, 359.1834).

Cespitaenin C (**8**): colorless, amorphous solid; $\left\lbrack \alpha \right\rbrack_{\text{D}}^{25}$ −35.5 (*c* 0.2, CH~2~Cl~2~); IR (neat) ν~max~ 3385, 2924, 1738 cm^−1^; ^1^H-NMR (CDCl~3~, 300 MHz) and ^13^C-NMR (CDCl~3~, 75 MHz) data, see [Table 1](#marinedrugs-13-05796-t001){ref-type="table"} and [Table 2](#marinedrugs-13-05796-t002){ref-type="table"}, respectively; HRESIMS *m*/*z* 361.2378 (\[M + Na\]^+^, calcd for C~22~H~32~O~4~Na^+^, 361.2379).

Cespitaenin D (**9**): colorless, amorphous solid; $\left\lbrack \alpha \right\rbrack_{\text{D}}^{25}$ 0.1 (*c* 0.2, CH~2~Cl~2~); IR (neat) ν~max~ 3444, 2986, 2950, 1731 cm^−1^; ^1^H-NMR (CDCl~3~, 500 MHz) and ^13^C-NMR (CDCl~3~, 125 MHz) data, see [Table 1](#marinedrugs-13-05796-t001){ref-type="table"} and [Table 2](#marinedrugs-13-05796-t002){ref-type="table"}, respectively; HRESIMS *m*/*z* 401.2306 (\[M + Na\]^+^, calcd for C~22~H~34~O~5~Na^+^, 401.2304).

Cespitaenin E (**10**): colorless, amorphous solid; $\left\lbrack \alpha \right\rbrack_{\text{D}}^{25}$ −20.6 (*c* 0.2, CH~2~Cl~2~); IR (neat) ν~max~ 3390, 2930, 1757 cm^−1^; ^1^H-NMR (CDCl~3~, 300 MHz) and ^13^C-NMR (CDCl~3~, 75 MHz) data, see [Table 1](#marinedrugs-13-05796-t001){ref-type="table"} and [Table 2](#marinedrugs-13-05796-t002){ref-type="table"}, respectively; HRESIMS *m*/*z* 401.2305 (\[M + Na\]^+^, calcd for C~22~H~34~O~5~Na^+^, 401.2304).

3.5. Preparation of (S)- and (R)-MPTA Esters (**1a** and **1b**) from **1** {#sec3dot5-marinedrugs-13-05796}
---------------------------------------------------------------------------

*R*-(−)- or *S*-(+)-MPTA chloride (one drop) was added to a solution of **1** (3 mg in 2 mL pyridine) and the solution was allowed to stand at room temperature for 12 h. After purification using preparative LC, the resultant ester (3 mg, 90% yield) was analyzed by ^1^H NMR spectroscopic measurement, and ∆ = δ*~S~* − δ*~R~* was calculated. *Compound **1a**:*^1^H-NMR (CDCl~3~, 300 MHz) δ~H~ 5.578 (1H, dd, *J* = 8.9, 7.2 Hz, H-6), 5.542 (1H, overlap, H-7), 1.199, 1.466 (6H, s, H-16, 17), 4.788 (1H, s, H-18), 4.770 (1H, s, H-18), 1.597 (3H, s, H-19), 4.12 (1H, t, *J* = 6.6 Hz, H-1′), 3.92 (1H, t, *J* = 6.6 Hz, H-1′), 3.89 (1H, m, H-2″), 3.25 (1H, m, H-2″); *Compound **1b**:* ^1^H-NMR (CDCl~3~, 300 MHz) δ~H~ 5.525 (1H, dd, *J* = 8.9, 7.2 Hz, H-6), 5.402 (1H, d, *J* = 8.9 Hz, H-7), 1.189, 1.444 (6H, s, H-16, 17), 4.871 (1H, s, H-18), 4.835 (1H, s, H-18), 1.586 (3H, s, H-19), 4.12 (1H, t, *J* = 6.6 Hz, H-1′), 3.92 (1H, t, *J* = 6.6 Hz, H-1′), 3.87 (1H, m, H-2″), 3.25 (1H, m, H-2″).

3.6. Cytotoxicity Assay {#sec3dot6-marinedrugs-13-05796}
-----------------------

Cytotoxicity was tested against the MCF-7 (breast carcinoma), Daoy (medulloblastoma), DLD-1 (colon adenocarcinoma), and Hela (cervical epitheloid adenocarcinoma) human tumor cell lines. The assay procedure using MTT \[3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide was carried out as previously described.\[[@B20-marinedrugs-13-05796]\] The cells were cultured in RPMI-1640 medium. After seeding of the cells in a 96-well microplate for 4 h, 20 µL of sample was placed in each well and incubated at 37 °C for three days, and then 20 µL MTT was added and allowed to stand for 5 h. Then the medium was removed and DMSO (200 µL/well) was added and the mixture was shaken for 10 min. The formazan crystals were redissolved and their absorbance was measured on a microtiter plate reader (MR 7000, Dynatech, Scottsdale, USA) at a wavelength of 550 nm. The ED~50~ value was defined by a comparison with the untreated cells as the concentration of test sample resulting in 50% reduction of absorbance. Mitomycin C was used as the positive control.

4. Conclusions {#sec4-marinedrugs-13-05796}
==============

This paper describes the first isolation of five novel nitrogen-containing diterpenoids and sesquiterpenoids, and five bicyclic verticillenes and nor-verticillenes from Taiwanese soft coral *Cespitularia taeniata*.
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